Nab-paclitaxel (Paclitaxel Protein-Bound) — Drug Monograph

Brand names: Abraxane

Drug class: Taxane

Mechanism of Action

Paclitaxel bound to albumin nanoparticles (130-nm particles). Albumin carrier allows Cremophor-free formulation, eliminating Cremophor-associated hypersensitivity reactions. Albumin-binding protein (SPARC/gp60) pathway facilitates preferential transcytosis into tumor tissue. Same microtubule-stabilizing mechanism as paclitaxel.

FDA Indications

• Metastatic breast cancer — after failure of combination chemotherapy or relapse within 6 months of adjuvant therapy
• Locally advanced or metastatic NSCLC — first-line with carboplatin (non-curative surgery/radiation candidates)
• Metastatic pancreatic cancer — first-line with gemcitabine

Common Side Effects

• Peripheral neuropathy (similar or less than Taxol)
• Myelosuppression
• Alopecia
• Fatigue
• Nausea
• Myalgias

Clinical Pearl

NOT interchangeable with Taxol — different doses, schedules, and formulation. Nab-paclitaxel does not require premedication and avoids Cremophor-mediated hypersensitivity. The albumin-binding mechanism may provide superior tumor penetration. In pancreatic cancer, Abraxane + gemcitabine (MPACT trial) demonstrated a landmark survival benefit, establishing this as a standard first-line option.

Related Therapies & Mechanisms

• Docetaxel (Taxotere) — Taxane · Breast
• Paclitaxel (Taxol) — Taxane · Breast
• Gemcitabine (Gemzar) — Breast
• Atezolizumab (Tecentriq) — NSCLC